|
A multicenter study of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors. |
|
|
Stock and Other Ownership Interests - MolecularMatch; Oncorena |
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack |
Consulting or Advisory Role - Baxter; Bayer; Guidepoint Global; Janssen |
Research Funding - Abbvie; Adaptimmune; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Genentech; Genmab; Ignyta; Infinity Pharmaceuticals; Kite, a Gilead company; Kyowa Hakko Kirin; Lilly; Loxo; MedImmune; Merck; Mirati Therapeutics; miRNA Therapeutics; Molecular Templates; Novartis; Pfizer; Takeda |
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics |
Other Relationship - Oncorena |
|
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; TaiRx, Inc. |
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Birdie (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Rexahn Pharmaceuticals (Inst); Santa Maria Biotherapeutics (Inst); Syndax (Inst) |
Travel, Accommodations, Expenses - Asana Biosciences |
|
|
No Relationships to Disclose |
|
|
Honoraria - Intellisphere, LLC |
Consulting or Advisory Role - 7 Hills Pharma; Actym Therapeutics; Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Gilead Sciences; Janssen; Merck; Newlink Genetics; Novartis; Reflexion Medical; Syndax; Tempest Therapeutics |
Research Funding - Abbvie; Boston Biomedical; Bristol-Myers Squibb; Celldex; Checkmate Pharmaceuticals; Corvus Pharmaceuticals; Delcath Systems; Five Prime Therapeutics; Genentech/Roche; Immunocore; Incyte; Macrogenics; MedImmune; Merck; Novartis; Palleon Pharmaceuticals; Pharmacyclics; Tesaro |
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Gilead Sciences; Janssen; Merck; Novartis; Reflexion Medical |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen |
Speakers' Bureau - Janssen |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen |
|
|
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Genentech; Merck |
|
|
Consulting or Advisory Role - Bayer; Merck |
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Pharmacyclics (Inst); Tesaro (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - genentech; Nestle health science |
Consulting or Advisory Role - Aduro Biotech; BeiGene; Celgene; Cornerstone Pharmaceuticals; EMD Serono; ERYTECH Pharma; Exelixis; Five Prime Therapeutics; Genentech/Roche; Gritstone Bio; Karyopharm Therapeutics; Opsona Therapeutics; Pierre Fabre; Symphony Evolution |
Research Funding - Abbvie (Inst); Bayer (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Loxo (Inst); Merrimack (Inst); Novartis (Inst); OncoMed (Inst); Pharmacyclics (Inst); Symphony Evolution (Inst); Taiho Pharmaceutical (Inst); Vertex (Inst) |
Travel, Accommodations, Expenses - Celgene; EMD Serono; Genentech/Roche; Nestle health science |
Other Relationship - AstraZeneca; Symphony Evolution |
|
|
Stock and Other Ownership Interests - COTA |
Consulting or Advisory Role - Bayer; Karyopharm Therapeutics; Lilly |
Speakers' Bureau - Bristol-Myers Squibb; Foundation One Inc; Lilly; Merck |
Research Funding - Abbvie (Inst); Acceleron Pharma (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Esanex (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Seagen (Inst); Tesaro (Inst); TG Therapeutics (Inst) |
|
|
Speakers' Bureau - Genentech |
|
|
|
Research Funding - ACEA Biosciences (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Xcovery (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Pharmacyclics |
Stock and Other Ownership Interests - Abbvie |
|
|
Leadership - Pharmacyclics |
Travel, Accommodations, Expenses - Pharmacyclics |
|
|
No Relationships to Disclose |